Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | NOD1 | Q9Y239 | 10/20 | 0.60 |
| ▸ | CXCL8 | P10145 | 4/20 | 0.60 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.55 |
| ▸ | NOS2 | P35228 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5991067 | 0.88 | SMN1; SMN2 (0.56) | SMN1; SMN2NOD1CXCL8NOD2GAA | |
| SCHEMBL4873241 | 0.81 | NOD1 (0.66) | SMN1; SMN2NOD1CXCL8NOD2GAA | |
| SCHEMBL3490377 | 0.81 | SMN1; SMN2 (0.74) | SMN1; SMN2NOD1CXCL8NOD2GAA | |
| SCHEMBL11148665 | 0.79 | SMN1; SMN2 (0.44) | SMN1; SMN2NOD1CXCL8NOD2GAA | |
| SCHEMBL11149114 | 0.79 | MAPK14 (0.47) | SMN1; SMN2NOD1CXCL8NOD2GAA | |
| SCHEMBL989419 | 0.79 | MAPK14 (0.49) | SMN1; SMN2NOD1CXCL8NOD2GAA | |
| SCHEMBL11246875 | 0.79 | PI4KB (0.46) | SMN1; SMN2NOD1CXCL8NOD2GAA | |
| SCHEMBL4839325 | 0.79 | MAPK14 (0.49) | SMN1; SMN2NOD1CXCL8NOD2GAA | |
| Water SCHEMBL11255021 | 0.78 | KMT2A (0.46) | SMN1; SMN2NOD1CXCL8NOD2GAA | |
| SCHEMBL4880923 | 0.78 | PI4KB (0.53) | SMN1; SMN2NOD1CXCL8NOD2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863310-B2 | Kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080227839-A1 | Kinase Inhibitors | ELI LILLY AND COMPANY | 2008-09-18 | — | — | US | disclosed |
| US-7320995-B2 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | ELI LILLY AND COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1720862-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1554272-B1 | BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE | LILLY CO ELI (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20050272791-A1 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | EIL LILLY AND COMPANY (US) | 2005-12-08 | — | — | US | disclosed |
| WO-2005080380-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
| EP-1554272-A1 | BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE | ELI LILLY AND COMPANY (US) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004014900-A1 | BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE | ELI LILLY AND COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
| US-4435394-A | 3-Sulfonamido-benzophenonimine derivatives useful for treating virus infections | SHIONOGI & CO., LTD. (JP) | 1984-03-06 | — | — | US | disclosed |
| US-4338329-A | COMBATTING RHINOVIRUSES | ELI LILLY AND COMPANY (US) | 1982-07-06 | — | — | US | disclosed |
| US-4316021-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1982-02-16 | — | — | US | disclosed |
| US-4289782-A | PARTICULARLY FOR INHIBITING GROWTH OF RHINOVIRUSES | ELI LILLY AND COMPANY (US) | 1981-09-15 | — | — | US | disclosed |
| US-4243813-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1981-01-06 | — | — | US | disclosed |
| US-4230868-A | α-Alkyl-α-hydroxybenzyl-substituted 1-sulfonylbenzimidazoles | ELI LILLY AND COMPANY (US) | 1980-10-28 | — | — | US | disclosed |
| US-4196125-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1980-04-01 | — | — | US | disclosed |
| US-4174454-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1979-11-13 | — | — | US | disclosed |
| US-4118742-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1978-10-03 | — | — | US | disclosed |
| US-4118573-A | ANTIVIRAL AGENTS | ELI LILLY AND COMPANY (US) | 1978-10-03 | — | — | US | disclosed |
| US-4018790-A | VIRICIDES | ELI LILLY AND COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272791-A1 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | MAP3K8, MAPK8, MAPK1 | SMN1; SMN2 4631/4885NOD1 1591/4885CXCL8 516/4885 |
| US-20080227839-A1 | Kinase Inhibitors | ABL1, MAP3K20, MAP3K19 | SMN1; SMN2 3611/4885NOD1 4801/4885CXCL8 4312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.